1,2,4-Oxadiazole Derivatives for Selective PD-1 Inhibition
Solution Overview
Problem
Current approaches for modulating the PD-1 signaling pathway, crucial for immune responses and cancer therapy, lack potent and selective immune modulators.
Innovation Solution
Development of 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds that inhibit the PD-1 signaling pathway, specifically designed to suppress or inhibit PD-1 signaling, with pharmaceutical compositions and methods for administration to treat various diseases, including cancer and infectious conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current approaches for modulating PD-1 signaling pathway are used, then immune modulation is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical parameters of the oxadiazole and thiadiazole core structures, including substituent types, positions, and combinations. This allows optimization of binding affinity and selectivity for PD-1 while maintaining manageable molecular complexity. The structured approach to modifying R1-R6 substituents enables precise tuning of immunomodulatory properties without excessive structural complexity.
2Productivity
If PD-1 pathway blockade is implemented, then immune responses against cancer are promoted, but risk of pathogenic autoimmunity increases
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns at different positions (R1-R6) of the oxadiazole/thiadiazole core. Different substituents at different positions provide localized interactions that enhance cancer-specific immune activation while maintaining selectivity that spares autoregulatory pathways. This spatially differentiated chemical design allows differential modulation of immune responses.
Solution Approach 2:
The patent employs partial action by developing compounds with moderate to high potency that selectively inhibit PD-1 signaling without complete pathway blockade. The structured substituent variations allow titration of immunomodulatory activity, providing sufficient anti-tumor effect while preserving enough endogenous PD-1 function to prevent autoimmune pathology.
3Reliability
If therapeutic antibodies blocking PD-1 are used, then T-cell down regulation is prevented, but device complexity and cost increase
Solution Approach 1:
The patent applies this principle by developing small molecule compounds with simpler structures compared to large therapeutic antibodies. The oxadiazole and thiadiazole derivatives are chemically synthesized small molecules that can be produced more economically and with simpler manufacturing processes than monoclonal antibodies, while still achieving reliable PD-1 pathway modulation and T-cell activation maintenance.
Data Source
AI summary
The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I)In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.